Lb Pharmaceuticals (LBRX)Ra Capital Management, L.P. added to its stake +432K shares

2.21M

Shares reported · +432K vs prior quarter

0.50%

Disclosed portfolio weight

$49.2M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 4, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)

What came next

1. Mar 4, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On March 6, 2026, the Board of Directors (the “Board”) of LB Pharmaceuticals Inc (the “Company”) appointed Robert A. Lenz, to the Board, effectively immediately.”
2. Mar 13, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 13, 2026, Zachary Prensky notified the Board of Directors (the “ Board ”) of LB Pharmaceuticals Inc (the “ Company ”) of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “ 2026 Annual Meeting ”).”
3. Mar 26, 2026Company filing · Form 8-K · ResultsReported its results
4. May 12, 2026Company filing · Form 8-K · ResultsReported its results
5. Jun 8, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Anna Eramo, M.D., for personal reasons will transition to a role of advisor to LB Pharmaceuticals Inc (the “ Company ”). On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the “ Separation Date ”).”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Lb Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Lb Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LBRX page.

How this filing works

• SEC Form 13F

Other disclosures at Lb Pharmaceuticals

• SEC Form 13F-HRNov 14, 2025
• SEC Form 13F-HRNov 14, 2025
• SEC Form 4Sep 16, 2025
• SEC Form 4Sep 16, 2025
• SEC Form 4Sep 16, 2025
• SEC Form 4Sep 16, 2025

Everything OQRO holds on this company is on its LBRX page.